Literature DB >> 8541026

Is early detection of ovarian cancer possible?

P E Schwartz1, K J Taylor.   

Abstract

Advances in medical technology have led to potentially useful techniques for the early detection of epithelial ovarian cancer. Early detection of ovarian cancer is crucial for survival as women found to have Stage I or II disease have a 5-year survival of 90% and 70%, respectively, whereas those with advanced disease (Stage III and IV) have a survival of approximately 20%. The circulating tumour marker CA-125 has been extremely useful in following women known to have epithelial ovarian cancers. It has been employed in differentiating benign tumours from malignancies, and is now being tested in a variety of programmes for its role in the early detection of ovarian cancer. The application of endovaginal ultrasound and colour Doppler flow techniques to early detection of ovarian cancer have resulted in several large series identifying ovarian cancer in 1:1000 to 1:2000 postmenopausal women screened. However, a high false positivity rate persists using CA-125 and ultrasound techniques alone or in sequence. Developments in molecular genetics may be extremely useful in evaluating women with inherited susceptibilities for this disease, but this probably represents only about 3% of the population of the women who develop epithelial ovarian cancer. The cost-benefit analysis of isolated screening for epithelial ovarian cancer using CA-125 and ultrasound techniques, even in women at high risk for the disease, would suggest that such screening is not cost-effective at this time.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541026     DOI: 10.3109/07853899509002463

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  7 in total

1.  Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

Authors:  Iva Sedláková; Jaroslava Vávrová; Jindřich Tošner; Ladislav Hanousek
Journal:  Tumour Biol       Date:  2011-04

2.  Improved survival in BRCA2 carriers with ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Rachna Kapoor; Alan Cantor; Rebecca Sutphen
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 3.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

Review 4.  Ovarian cancer: the clinical role of US, CT, and MRI.

Authors:  Kaori Togashi
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

5.  Identification of five serum protein markers for detection of ovarian cancer by antibody arrays.

Authors:  Weidong Jiang; Ruochun Huang; Chaohui Duan; Liwu Fu; Yun Xi; Yuebo Yang; Wei-Min Yang; Dongzi Yang; Dong-Hua Yang; Ruo-Pan Huang
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

6.  Relative Ratios Enhance the Diagnostic Power of Phospholipids in Distinguishing Benign and Cancerous Ovarian Masses.

Authors:  Tsukasa Yagi; Cyrus E Kuschner; Muhammad Shoaib; Rishabh C Choudhary; Lance B Becker; Annette T Lee; Junhwan Kim
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

7.  Characterisation of human kallikrein 6/protease M expression in ovarian cancer.

Authors:  X Ni; W Zhang; K-C Huang; Y Wang; S-K Ng; S C Mok; R S Berkowitz; S-W Ng
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.